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Abstract
Background: Nesprins (Nuclear envelope spectrin-repeat proteins) are a novel family of giant spectrin-repeat containing
proteins. The nesprin-1 and nesprin-2 genes consist of 146 and 116 exons which encode proteins of ,1mDa and ,800 kDa
is size respectively when all the exons are utilised in translation. However emerging data suggests that the nesprins have
multiple alternative start and termination sites throughout their genes allowing the generation of smaller isoforms.
Results: In this study we set out to identify novel alternatively transcribed nesprin variants by screening the EST database
and by using RACE analysis to identify cDNA ends. These two methods provided potential hits for alternative start and
termination sites that were validated by PCR and DNA sequencing. We show that these alternative sites are not only
expressed in a tissue specific manner but by combining different sites together it is possible to create a wide array of
nesprin variants. By cloning and expressing small novel nesprin variants into human fibroblasts and U2OS cells we show
localization to actin stress-fibres, focal adhesions, microtubules, the nucleolus, nuclear matrix and the nuclear envelope (NE).
Furthermore we show that the sub-cellular localization of individual nesprin variants can vary depending on the cell type,
suggesting any single nesprin variant may have different functions in different cell types.
Conclusions: These studies suggest nesprins act as highly versatile tissue specific intracellular protein scaffolds and identify
potential novel functions for nesprins beyond cytoplasmic-nuclear coupling. These alternate functions may also account for
the diverse range of disease phenotypes observed when these genes are mutated.
Citation: Rajgor D, Mellad JA, Autore F, Zhang Q, Shanahan CM (2012) Multiple Novel Nesprin-1 and Nesprin-2 Variants Act as Versatile Tissue-Specific
Intracellular Scaffolds. PLoS ONE 7(7): e40098. doi:10.1371/journal.pone.0040098
Editor: Krishna Sharma, University of Missouri-Columbia, United States of America
Received March 12, 2012; Accepted May 31, 2012; Published July 2, 2012
Copyright:  2012 Rajgor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Medical Research Council and the British Heart Foundation provided funding for this study. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cathy.shanahan@kcl.ac.uk
. These authors contributed equally to this work.
Introduction
Nuclear envelope (NE) spectrin-repeat proteins, or nesprins, are
a novel family of nuclear and cytoskeletal proteins with rapidly
expanding roles as intracellular scaffolds and linkers [1,2,3,4].
Nesprins are characterized by a central extended spectrin-repeat
(SR) rod domain and a C-terminal Klarsicht/ANC-1/Syne
homology (KASH) transmembrane domain, which acts as a NE
targeting motif. At the NE, via interactions with the Sun-domain
family of proteins and the nuclear lamina, nesprins on both the
inner and outer nuclear membrane form the linker of the
nucleoskeleton and cytoskeleton (LINC) complex [5,6]. This
complex requires the giant nesprin-1 (,1 MDa) and nesprin-2
(,800 kDa) isoforms, which possess a pair of N-terminal calponin
homology domains, which bind directly to F-actin [7,8]. Nesprin-3
(,110 kDa) and nesprin-4 (,43 kDa) are smaller family members
with more divergent spectrin-repeats. These lack the N-terminal
CH domains of nesprin-1 and -2 and via SRs interact with
intermediate filaments and microtubules respectively [3,4,9].
Disruption of the LINC complex via mutations in nesprin-1 and
-2 or their binding partners, such as emerin and lamin A/C, give
rise to Emery Dreifuss Muscular Dystrophy (EDMD)
[6,10,11,12,13,14,15,16,17]. However, emerging evidence impli-
cates nesprin-1 and -2 in several other unrelated diseases,
including schizophrenia, epithelial cancers and autosomal reces-
sive cerebellar ataxia (ARCA1), which are not characterized by
NE defects [18,19,20]. It is likely that these non-canonical roles for
nesprin are mediated by alternative transcription that has been
shown to generate multiple tissue-specific nesprin variants that
lack either the CH domain, the KASH domain or both and
localize to a number of subcellular compartments [2,21]. For
example, nesprin-1 has been shown to localize to the Golgi
apparatus and over-expression of dominant-negative nesprin-1
fragments composed of SRs within the central rod domain disrupt
Golgi organization and function [22,23,24]. Nesprin-1 isoform
Drop1, which consists of the N-terminal CH domain and SRs but
lacks the KASH domain, is significantly down regulated in
epithelial cancer and may play a role in chromatin organization
[16,25,26]. Furthermore, the brain-specific nesprin-1 isoform,
candidate plasticity gene 2 (cpg2), consists solely of SRs and
localizes to the neuronal postsynaptic endocytic zone surrounding
dendritic spines where it regulates clathrin-mediated uptake and
recycling of chemokine receptors [27,28].
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functionality, in this study we set out to identify novel nesprin
variants by identifying 59UTRs and 39UTRs transcribed from the
nesprin-1 and nesprin-2 genes. We provide evidence that both
nesprin-1 and -2 undergo alternative splicing and express multiple
tissue specific variants generated by alternate initiation and
termination and that the sub-cellular localization of these variants
is cell type dependent. We also provide a unifying nomenclature
system for nesprin variants and their UTRs.
Results
Identification of Novel Nesprin-1 and Nesprin-2 UTRs
We adopted two approaches to identify bone fide novel 59 and
39UTRs. We first performed 59 and 39 RACE from HeLa, Skeletal
Muscle and Brain cDNA libraries using multiple gene specific
nesprin primers and nested primers designed towards the end of a
range of exons throughout the nesprin gene. Many PCRs
produced non-specific or no amplicons (data not shown) however,
products for multiple UTRs as retained introns were detected
(Figure 1A). For nesprin-1 we identified N1-59E83, a novel 59UTR
where the first coding exon utilised is exon 83. Multiple nesprin-1
39UTRs were detected in a tissue/cell specific manner where the
last coding exons were either exons 14, 44, 82, 90 or 106 (N1-
39E14, N1-39E44, N1-39E82, N1-39E90 and N1-39E106 respec-
tively). Similarly N2-39E50 and N2-39E90 are two novel nesprin-2
39UTRs also identified by RACE. The stop codons for isoforms
terminating with these novel 39 ends were found in retained
intronic sequences between the last coding exon and the exon
thereafter. In nesprin variants using these 39 ends the ‘retained
intron’ resulted in the addition of unique amino acids followed by
a stop codon that were absent from the giant isoforms.
Downstream of the stop codon will be a polyA signal followed
by a polyadenylation site. For example, variants terminating with
the N1-39E90 UTR contain eight codons before the stop codon in
the retained intron between exon 90 and exon 91. Thus variants
terminating with this 39UTR possess a novel 8 amino acid peptide
sequence, ‘AGAGYPHQ*’, which is absent in the giant isoform
(Figure 1B).
Due to limitations with RACE analysis we next screened
available databases for novel nesprin cDNA transcripts. The
NCBI expressed sequence tag database (EST), which consists of
one-shot sequences of cloned mRNA, was blasted with consecu-
tive, 500 bp-overlapping 1 kb nesprin-1 and nesprin-2 sequences
covering the entirety of the giant isoform cDNAs. Several novel
UTRs were detected in the EST database screen, typically
presenting as retained introns between two exons (Table 1).
59UTRs were considered real if they contained an identifiable and
viable Kozak sequence surrounding the first start codon. Only
those 39UTR sequences which already included a poly(A) tail or
contained at least one poly(A) site downstream of the initial ORF
termination codon, as determined by scanning with the polyAdq
program or manually for non-canonical poly(A) signals, were
considered for further study.
The majority of UTRs identified by RACE or through the EST
screen were verified by PCR and DNA sequencing using a multi-
tissue cDNA panel (Figures 1C,D. Table 1 contains a column
showing the UTRs which have been verified by PCR). PCR
primers were designed so that one primer was present within the
UTR and the second within a constitutively present exon with at
least one intervening intron sequence to control for genomic DNA
contamination. Although many UTRs PCR amplified in a range
of tissues, most were transcribed in a tissue specific manner
suggesting they lead to the creation of tissue specific nesprin
variants. The potential combinations of 59 UTRs with 39UTRs are
extensive and would allow generation of many variants. Figures 2A
and 3A provide an outline of the nesprin-1 and nesprin-2 UTRs
across their respective genes with figures 2B and 3B highlighting
proposed variants that could be created by a ‘mix-and-match’
approach in vivo for nesprin-1 and nesprin-2 respectively (Table S1
and Table S2 shows the UTRs that when combined generate these
nesprin-1 and -2 variants respectively). The spectrin repeats (SRs)
used in our schematics to represent nesprins are based on the
predictions of SRs as previously described [29]. Many of the
predicted nesprin variants are too large to be detected by
conventional PCR and are therefore hypothetical. The smaller
nesprin variants were however validated by PCR and are
described below.
Although many variants could retain the KASH domain, there
is a possibility of generating isoforms composed solely of SRs.
Therefore, the identified nesprin variants were named according
to their predicted molecular weights and the domains they
possessed. For example, p56CH
Nesp1 is a nesprin-1 variant of
56 kDa which has the N-terminal CH domains, p50
Nesp1 is a
50 kDa nesprin-1 variant which lacks both the CH domains and
the KASH domain and is composed of SRs, while p53KASH
Nesp1
is a 53 kDa KASH containing variant lacking CH domains.
Variants that lack the KASH domain due to alternative splicing
events in and around the exons coding for the KASH domain have
been described as DKASH variants (See below).
Nesprin KASH Isoforms
So far a number of KASH variants including the nesprin-1 and
nesprin-2 a,b isoforms have been identified. In principle any of the
59UTRs identified in this study could be utilised with the 39UTR
of the nesprin-1 giant to make KASH containing NE localized
nesprin variants. Whilst most 59UTRs are too distant from the
KASH domain for PCR amplification we were able to verify
p53KASH
Nesp1 (Accession number JQ754366), the smallest
nesprin-1 KASH containing isoform identified to date, with a
molecular weight of 53 kDa. p53KASH
Nesp1 uses the N1-59E138
alternative start site which was detected in heart, spleen, lung,
brain, prostate, PBL, small intestine (SI), ovary and liver cDNA
(Figure 1C). Although full-length p53KASH
Nesp1 could not be
detected in a range of primary and transformed cell lines it was
detected in tissues including heart, spleen and peripheral blood
leukocytes (PBL) (Figure 4F). Flag-p53KASH
Nesp1 cloned from
heart cDNA confirmed NE localization when transfected into
U2OS cells (Figure 4A,B).
Nesprin Calponin Homology Domain containing Isoforms
Next we set out to identify the sub-cellular localizations of
KASH-less nesprin variants composed of SRs or CH domains.
p56CH
Nesp1 and p32CH
Nesp2 are two nesprin CH-domain
containing variants with a Mw suitable for PCR amplification
and cloning (Accession numbers JQ740783 and JQ754367
respectively) (Figures 4A,E). p56CH
Nesp1 initiates with the most
upstream nesprin-1 UTR utilised by the nesprin-1 giant and
terminates with N1-39E14, encoding a protein that possesses the
CH domains and the first SR of nesprin-1. p32CH
Nesp2 terminates
upstream of the first SR coding exon and is therefore the only
known nesprin variant to date which lacks any SRs. Interestingly
we observed differential sub-cellular localizations when
p56CH
Nesp1 was transfected into transformed and primary cell
lines. In U2OS cells p56CH
Nesp1 surprisingly localized to the
nucleolus while in HDFs it associated with actin stress fibres and
focal adhesions (Figure 4C,D). Whilst p56CH
Nesp1 expression was
ubiquitously detected in all cell lines examined, expression of
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Nesp2 was limited to PBL, MBs and U2OS cells (Figure 4F).
Unlike p56CH
Nesp1, p32CH
Nesp2 localized to focal adhesions
when ectopically expressed in its native U2OS cells (Figure 4E).
Nesprin Central Rod Isoforms
Multiple 59 and 39 UTRs were identified in the nesprin-1 gene
between exons 83 and 90, suggesting that it is a region where
multiple variants are generated (Figure 5A). Using RACE we
identified a 59UTR where the first coding exon was exon 83 (N1-
59E83) and a 3‘UTR where the final coding exon was exon 90
(N1-39E90) (Figure 1A). Furthermore online databases revealed an
additional 59UTR associated with exon 84 (N1-59E84) and a
previously described Kazusa clone KIAA1262. The KIAA1262
sequence includes exons 77 to 87 and terminates in a 39UTR
where the final coding exon is exon 87 (N1-39E87). The
identification of these new UTRs together with the pre-existing
nesprin-1b1 and nesprin-1b2 59UTRs confirms that this is a region
of nesprin with the ability to generate multiple alternative
transcripts (Figure 5A).
Hypothetically these UTRs could generate 7 nesprin-1 splice
variants by alternative initiation and termination of the four
59UTRs with the three 39UTRs (Figure 5A). To test this, PCR
amplification from 59 to 39UTRs were carried out in multiple
tissue cDNA panels to see if any of the variant messages were
transcribed. p50
Nesp1 (Accession number JQ740784) expression
was ubiquitous while expression of the p41
Nesp1 (Accession
number JQ740786), p31
Nesp1(Accession number JQ740785),
p23
Nesp1 (Accession number JQ754364) and p12
Nesp1 (Accession
Figure 1. Identification of novel nesprin UTRs. A) cDNA ends identified by 39 and 59 RACE from Brain, Skeletal Muscle (SkeMus) and HeLa cDNA
libraries. B) DNA sequencing results suggest that nesprin isoforms terminate with unique C-terminal ends absent from the giant isoforms as a result of
intron retention. For example, isoforms utilising the N1-39E90 UTR terminate with ‘AGAGYPHQ’ amino acids, giving it a unique fingerprint. Blue
sequences show the coding regions of exons 90 and 91, black sequences show intronic regions and red sequence indicates a stop codon. C)
Validation and tissue specificity of nesprin-1 UTRs identified on online databases and by RACE were confirmed by PCR amplification from a multiple
tissue cDNA panel and DNA sequencing. Nesprin-1 PCRs were carried out when UTRs were identified on cDNA panels available at the time and are
therefore organised into 3 separate sections. D) Validation and tissue specificity of nesprin-2 UTRs identified on online databases and by RACE were
confirmed by PCR amplification from a multiple tissue cDNA panel and DNA sequencing. Nesprin-2 PCRs were carried out when UTRs were identified
on cDNA panels available at the time and are therefore organised into 3 separate sections. Small Intestine and Peripheral Blood Lymphocytes have
been abbreviated as ‘SI’ and ‘PBL’ respectively for all cDNA panels.
doi:10.1371/journal.pone.0040098.g001
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p30
Nesp1 and p20
Nesp1 failed to amplify and therefore are probably
not expressed (Figure 5A). When p50
Nesp1 was expressed in U2OS
cells it localized to and polymerized microtubules while all the
other isoforms displayed a diffuse cytoplasmic and nuclear
localization (Figure 5B for Flag- p50
Nesp1 and Flag- p31
Nesp1).
All other isoforms are shown in Figure S1A). p23
Nesp1 and
p12
Nesp1 both localized to and disrupted nucleolar morphology
when expressed in HDFs, causing fibrillarin to redistribute into
peri-nucleolar caps, while the slightly larger p31
Nesp1 localized
with fibrillarin without affecting its localization (Figure 5C). When
p41
Nesp1 was expressed in HDFs, it displayed diffuse cytoplasmic
localization and also concentrated around the ER (Figure S1B).
Another central rod variant Nesprin-1 p55
Nesp1, is composed of
a single SR and lacked both the CH and KASH domains
(Figure 5D). p55
Nesp1 was detected in the kidney, spleen and PBL
by PCR and displayed diffuse cytoplasmic localization when
transfected into U2OS cells (Figure 5D).
Nesprin Isoform Expression is Highly Adaptable
To further confirm the validity of the novel variants and
because previous evidence indicates that nesprins have the ability
to self-compensate we decided to investigate how knocking down a
sub-set of transcripts would effect expression levels of variants
encoded by nearby transcripts [30]. By designing an siRNA
targeting exon 90 (si-90) we were able to monitor by qRT-PCR
the levels of transcripts terminating with N1-39E87 and N1-39E90
UTRs (Figure 6). In theory this siRNA should target all transcripts
terminating with N1-39E90 but have no effect on N1-39E87
terminating transcripts as this termination site is located to the 59
end on exon 87. As expected, si-90 significantly reduced levels of
N1-39E90 expression but more interestingly also significantly
knocked down levels of the transcripts terminating with N1-39E87.
Furthermore si-136, an siRNA designed towards the KASH
domain of nesprin-1 increased expression of N1-39E87 transcripts,
showing that perturbations in the expression of one transcript can
influence expression of other downstream transcripts. Conversely
no change in N1-39E90 was detected with si-136, however both
siRNAs knocked down levels of nesprin-1 KASH expressing
transcripts (Figure 6).
Nesprin and Alternative Splicing of Cassette Exons
Next we set out to determine whether any of the 100 plus exons
of the nesprin-1 and nesprin-2 genes have the ability to undergo
alternative splicing to increase further variant diversity. As a
starting point we used nesprin EST and nucleotide databases to
look for potential splicing events which identified cassette exons 69,
93 and 145 for nesprin-1 (Table 2). Exon 69 is a potential isoform
Table 1. UTRs identified through online databases.
Gene UTR 59 or 39 Location NCBI Accession
Verified by
PCR
Nesprin-1 N1-59I14/15 59 Intron 14–15/ DA151121, CR933676, AK055440, BG197747, DB324328 +
Nesprin-1 N1-39E18 39 Exon 18 BC028616, DB545136, DB540697, DB538738 +
Nesprin-1 N1-59I18/19 59 Intron 18–19 DA337073 2
Nesprin-1 N1-39E20 39 Exon 20 DB540697, DB545136, DB538738 2
Nesprin-1 N1-59I21/22 59 Intron 21–22 DA337073 +
Nesprin-1 N1-39E25 39 Exon 25 DA151121, CR933676, AK055440, BG197747, DB324328 +
Nesprin-1 N1-39E37 39 Exon 37 AL713682 +
Nesprin-1 N1-59E44 59 Exon 44 DB300122 2
Nesprin-1 N1-39E62 39 Exon 62 BC039121,CA425673,AW300380, BG203678, BG210617, DB516174,
CA441052, BX093712,CA312508, DB319424, AA227537,AI866946
+
Nesprin-1 N1-59E84 59 Exon 84 BU461222 2
Nesprin-1 N1-39E87 39 Exon 87 AB033088 2
Nesprin-1 N1-59E92 59 Exon 92 CJ462692, DA229059, DA227411, DA212433, DA509325, DB059554,
DA802484, EE366817, DA241105, DA338782, DB289567, DA116814,
DA493491
+
Nesprin-1 N1-59E97 59 Exon 97 BF740426, BF726175 2
Nesprin-1 N1-59I128/129 59 Intron 128–129 AK304825 +
Nesprin-1 N1-59I132/133 59 Intron 132–133 DA632075 2
Nesprin-1 N1-59E138 59 Exon 138 DA827648 +
Nesprin-2 N2-39E9 39 Exon 9 BC042134, BC071873 +
Nesprin-2 N2-39E46 39 Exon 46 BX648234 +
Nesprin-2 N2-59E49 59 Exon 49 BC036941, BI860943,AA247756 +
Nesprin-2 N2-59E63 59 Exon 63 CV571029 2
Nesprin-2 N2-59I 91/92 59 Intron 91–92 DA226447 +
Nesprin-2 N2-59I 99/100 59 Intron 99–100 DB089560, BM805144, DB088145, DA810994, DA725349, DA101036,
DB152052, DA196319, DA706514, DA186088, DA106538, DA093934,
DA334037, DA333629, DB063748, DA222451, DA230417, DA097798,
DA094004, DA522676
+
Table listing all potential UTRs identified through available online databases.
doi:10.1371/journal.pone.0040098.t001
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encodes a 7 amino acid peptide insert at the end of the first CH
domain of nesprin-1 (See Figure S2A for nesprin-1 genomic map
with cassette exon). Exon 93 contributes an additional 47 amino
acids to a SR of the central rod domain while exon 145 encodes a
peptide sequence at the C-terminal region of the KASH domain.
Several alternatively spliced exons, were also identified in
nesprin-2 using the same data mining procedure, including
cassette exons 1019, 1079 and 114 and 59 alternatively spliced
exons 110 to 113 (Table 2). Unlike nesprin-1, the identified exons
were all located near the C-terminal half of the nesprin-2 giant.
Splicing of exons 1019, 1079, 110 to 113 and 114 would alter the
length of the coiled-coil regions surrounding the two SR preceding
the KASH domain while removal of the first 31aa encoded by
exon 113 would eliminate the final SR before the KASH domain.
As with exon 69 of nesprin-1, exon 1019 and 1079 of nesprin-2
represent coding regions which maybe isoform or tissue specific
and are located between exons 101 to 102 and 107 to 108
respectively. (See Figure S2B for nesprin-2 genomic map with
cassette exons).
To identify whether these splicing events did indeed take place
we designed primers to exons either side of the cassette exons and
carried out PCR analysis from U2OS and VSMC cDNA libraries
(Figure 7A,B). For nesprin-1, two PCR products appeared from
U2OS and VSMC libraries when PCR amplification was carried
out across exon 93; the larger of the two bands included exon 93
and the smaller band with the exon excluded. Nesprin-2 splicing
showed more tissue specificity than nesprin-1, with PCR products
including and excluding cassette exon 1079 expressed in U2OS
cells at equal quantities while in VSMCs exon 1079 was exclusively
expressed with no band detected for transcripts with the exon
excluded expressed. Furthermore in VSMCs, transcripts with
exons 110–113 removed were detected as well as transcripts with
the exons included, although transcripts with the exons included
seem to be transcribed in greater abundance. U2OS cells only
expressed transcripts with the exons included.
Although splicing of cassette exons 69 of nesprin-1 and exon 28–
31, 1019 and 114 for nesprin-2 failed to be detected in this set of
PCRs, examination of a wider array of cells and tissues is required
to determine whether the splicing events listed in the databases
occur.
Nesprin DKASH Isoforms
The search for potential splicing events for nesprin also revealed
splice events that eliminate the KASH domain. Alternative
splicing of cassette exon 145 of nesprin-1, results in a frame shift
that removes the KASH domain to create Nesprin-1DKASH (N1-
DKASH) (Figure 8A). Though the same 39UTR adjacent to exon
146 is shared between KASH domain and N1-DKASH sequences,
the removal of exon 145 results in a change in the open reading
frame of N1-DKASH variants and therefore they terminate with a
novel 11aa tail: VHKRWLRFLPF rather than the RYTNGPPPL
sequence utilized by KASH containing variants. Expression of N1-
DKASH isoforms was detected in all tissue cDNA examined by
PCR, suggesting that this splicing and resultant variants are
ubiquitously expressed (Figure 8D). When the DKASH variant of
p53KASH
Nesp1 (p53DKASH
Nesp1) lacking exon 145 was trans-
fected into U2OS cells it no longer resided at the NE, but instead
displayed strong nuclear matrix localization and weak cytoplasmic
staining (Figure 8A).
Unlike N1-DKASH, nesprin-2 possesses two mechanisms for
creating DKASH variants (Figure 8B,C). Like nesprin-1, genera-
tion of N2-DKASH1 occurs via the removal of cassette exons 110
to 113 but uses the same 39UTR as the KASH variant. This
splicing event results in a change in the ORF and therefore N2-
DKASH1 terminates with a GIAGHSATPPA amino acid
sequence rather than the YPMLRYTNGPPPT sequence used
by KASH containing isoforms. N2-DKASH2 is created by a novel
39UTR immediately adjacent to the 39 end of exon 115. N2-
DKASH2 splicing truncates larger isoforms without generating a
novel C-terminal peptide. The N2-DKASH1 splicing was pre-
dominantly detected in the brain and kidney with smaller amounts
being amplified from the heart, where the lower band represents
the removal of the cassette exons promoting N2-DKASH1
formation (Figure 8D). The N2-DKASH2 termination was
detected in the heart and spleen only (Figure 8D).
Discussion
Nesprins as Adaptable, Tissue Specific, Intracellular
Scaffolds
This study has demonstrated that nesprins, by generating
variants via alternative transcriptional initiation and termination
show localizations and therefore functions independent of their
original description as NE linkers and scaffolds. Although nesprin-
1 has the potential to generate more isoforms than nesprin-2, with
more UTRs spread across the gene, the nesprin-2 isoforms are
primarily N-terminal truncations that would retain the KASH
domain. This suggests that nesprin-1 may have more functions
beyond the NE than nesprin-2 or that sequences near the highly
conserved C-terminus of nesprin-2 are important for cell function
[29]. To our knowledge, the potential combinations of UTRs and
exon splicing are unlimited. This combined with the ability of
nesprins to dynamically regulate variant expression would allow
cells to fine-tune their nesprin isoform repertoire as needed to
maintain and restore homeostasis following stress or to regulate
tissue-specific signalling pathways [31]. As a proof of principle we
were able to show that nesprin transcription appears to be highly
adaptable with a feedback loop regulating nesprin variant
expression. For example we demonstrate using siRNAs that by
knocking down a region of nesprin-1 near the KASH domain we
were able to upregulate expression of N1-39E87 UTR transcripts.
Furthermore nesprin-2 CH domain knockout mice display an
altered expression pattern for specific nesprin-2 C-terminal
isoforms in certain tissues to compensate for the loss of nesprin-2
giant or nesprin-2 actin binding domain isoforms [30]. These
observations suggest that nesprin alternative transcript generation
is highly flexible and more complex than a simplified tissue-specific
expression model.
Generation, Regulation and Function of Novel Tissue
Specific Nesprin Variants via Alternative Initiation and
Termination
Using 59 and 39RACE as well as sequences in the EST
database, followed by PCR amplification and DNA sequencing,
we identified multiple novel sequence variants for nesprin-1 and -
2. RT-PCR was used to establish the existence of mRNA
Figure 2. Potential nesprin-1 isoforms. A) Genomic map of the nesprin-1 gene highlighting the positions of the nesprin-1 UTRs identified to
date. B) Proposed nesprin-1 isoforms created by alternative transcription. SRs are numbered and shown according to the scheme of Simpson and
Roberts 2008 and are shown to scale.
doi:10.1371/journal.pone.0040098.g002
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PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e40098Figure 3. Potential nesprin-2 isoforms. A) Genomic map of the nesprin-2 gene highlighting the positions of the nesprin-1 UTRs identified to
date. B) Proposed nesprin-2 isoforms created by alternative transcription. SRs are numbered and shown according to the scheme of Simpson and
Roberts 2008 and are shown to scale.
doi:10.1371/journal.pone.0040098.g003
Identification of Novel Nesprin-1/-2 Variants
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e40098Identification of Novel Nesprin-1/-2 Variants
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e40098transcripts for full-length short isoforms or for the novel UTRs of
potentially larger variants. The multiple UTRs allow nesprins to
express a large number of sequence variants via alternate initiation
and termination and many of these were generated in a tissue
specific manner. Therefore, in addition to the novel UTR’s
verified in this study it is likely that by performing RACE in a
greater collection of cells/tissues we may be able to identify further
nesprin alternate initiation and termination sites.
To date, the mechanisms of tissue specific generation of nesprin
variants has not been studied. Analysis of the human transcrip-
tome shows a direct correlation between alternative promoter use
and alternative splicing [32]. Alternative promoters can produce
mRNAs with different 59UTRs that encode the same protein,
distinct N-termini, and even different proteins from the same locus
[33,34,35,36]. The identification of multiple, novel 59UTRs in
both nesprin-1 and -2 indicated the presence of several internal
alternative promoters. The existence and regulation of alternative
nesprin promoters has not yet been explored but this study
suggests that these promoters are utilised in a tissue specific
manner. Furthermore, because many individual variants have
unique pairs of 59 and 39UTRs, additional control and regulation
of variant expression can be maintained. The 59UTR is an
important regulator of mRNA translation and can contain
regulatory motifs/sequences which affect the rate of translation
as well as containing a kozak sequence upstream of the start codon
which plays a major role in determining the translational strength
of the transcript [37,38]. The 39UTR of mRNA transcripts can
play a role in mRNA localization, stability, and translation
[39,40,41,42]. For example, binding of miRNAs to partially
complementary sequences in the 39UTR can result in de-
adenylation and translational inhibition or destruction of the
target mRNA [43,44]. A RegRNA scan of both the nesprin 59 and
39UTRs for regulatory RNA motifs detected several potential
miRNA binding sites which were transcript specific and could
potentially regulate variant translation (data not shown).
Importantly, we showed that many of the variants generated
through retained introns had generated unique peptide sequences.
It is highly likely that these sequences expose new functional
domains that give the variants additional localization signals or
motifs that play an important role in their function. For example,
ELM analysis predicts a novel retinoblastoma (Rb) interacting
motif found in cell cycle regulatory proteins at the C-terminal end
of p220CH
Nesp2 while the N-terminus of p931KASH
Nesp1
contains a potential N-myristoylation site, a post-translational
modification which facilitates membrane anchoring [45,46,47].
ELM analysis also predicts multiple PKA, MAPK and CDK
phosphorylation sites in the unique sequences of p32CH
Nesp2,
p56CH
Nesp1 and p55
Nesp1. To further explore this hypothesis
yeast-2-hybrid analyses or co-immunoprecipitation assays will be
required to identify binding partners for specific nesprin variants.
The ultimate validation for each proposed variant will be the
detection of their translation and expression by western blotting.
Post-translational modifications such as phosphorylation, sumoy-
lation, and enzymatic cleavage may be partially responsible for the
range of western bands often visualized using the currently
available anti-nesprin antibodies [1,17,48]. Designing isoform-
specific antibodies will help to distinguish between modifications
and splicing.
Alternative Splicing of Cassette Exons may Diversify
Nesprin Function and Localization
In addition to alternative initiation and termination, we showed
that some of the cassette exons located in the EST database are
indeed valid. It is unclear whether these splice events occur in
multiple variants or are isoform specific but they are likely to
substantially increase nesprin diversity, likely in a tissue specific
manner. This notion was supported by the observation that while
some splice events occurred in the majority of cell lines, some
events seemed to be cell type specific. For example unlike the
nesprin-1 DKASH which was detectable in all cells tested, the
splicing event of cassette exons which generate nesprin-2 DKASH
seem to be very tissue specific. Furthermore the ability for nesprin-
2 to generate DKASH variants via 2 different mechanisms, one by
the utilization of a unique 39UTR and another by the splicing of
exons 110–113 suggest that the C-terminal ends of the DKASH
variants may serve unique tissue specific functions at sites away
from the NE.
Although in this study we did not look specifically at the effects
of structure, function and localization of nesprin variants with and
without alternate splicing of the cassette exons we did show that
some of these splicing events also created unique peptides.
Nesprin-1 exon 93 encodes a unique 47 amino acid peptide
sequence and nesprin-2 exon 1079 encodes a unique 23 amino
acid peptide. Although these peptide sequences are not very large
they may be capable of encoding novel localization signals or
binding sites for interactions with other proteins. Our next aim will
be to create nesprin variants with and without these exons so we
can identify their putative roles in nesprin function.
However we were able to show that KASH-less nesprin
isoforms displayed subcellular localizations which varied depend-
ing on the cell lines they were expressed in. In U2OS cells
p56CH
Nesp1 localized to the nucleolus while the same protein
localized along actin cables and focal adhesions in HDFs.
Currently we do not understand what determines this differential
change in subcellular localizations but we speculate that the
presence of endogenous p32CH
Nesp2 at focal adhesions in U2OS
cells (p32CH
Nesp2 is not expressed in HDFs but is expressed in
U2OS) is enough for p56CH
Nesp1 function to become redundant
at focal adhesions in U2OS. Furthermore we suspect that
differences in the actin cytoskeleton may play a role in differential
localization of p56CH
Nesp1. The nesprin-1 CH domains contain
two nuclear localization signals which may be utilized in cells with
low actin levels such as U2OS cells but not in structural cells such
as HDFs where there is plenty of actin for the protein to bind to
[49]. Alternatively, potential p56CH
Nesp1 phosphorylation events
predicted by ELM analysis may occur in a tissue specific manner
which may contribute to the differences seen in localizations
between the two cell types. Similarly differential sub-cellular
localizations were seen when central rod isoforms p12
Nesp1,
Figure 4. Cloning and expression of novel Nesprin KASH and CH isoforms. A) Schematic representation of p53KASH
Nesp1 (Accession
numberJQ754366) and p56CH
Nesp1 (Accession number JQ740783) relative to the nesprin-1 giant. B) p53KASH
Nesp1 localizes to the NE when
transfected into U2OS cells. C) Nesprin-1 Flag-p56CH
Nesp1 localized to the nucleolus when transfected into U2OS cells. D) Nesprin-1 Flag-p56CH
Nesp1
localizes to actin stress fibres and with Focal Adhesion Kinase (FAK) at focal adhesions when transfected into Human Dermal Fibroblasts (HDFs). E)
Nesprin-2 Flag-p32CH
Nesp2 (Accession numberJQ754367) co-localized with FAK at focal adhesions when transfected into U2OS cells. F) p53KASH
Nesp1
expression was not detected by PCR in U2OS, Human Dermal Fibroblasts (HDFs), Vascular Smooth Muscle Cells (VSMCs) or Myoblasts (MBs), however
it was detected in the heart, spleen and peripheral blood leukocytes (PBL). p56CH
Nesp1 was detected in all cells and tissues examined whereas
p32CH
Nesp2 was limited to U2OS cells, MBs and PBL.
doi:10.1371/journal.pone.0040098.g004
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Nesp1 and p31
Nesp1, were transfected into U2OS and HDFs. In
U2OS cells all isoforms displayed diffuse cytoplasmic localization
while in HDFs nucleolar localization was observed. Differences in
post-translational modifications could vary between the two cell
lines or the proteins may have different binding partners in each
cell line which could contribute to differential localizations.
Ultimately the localization of these isoforms would have to be
monitored in cells that express the variant endogenously.
Isoforms and Disease
Multiple nesprin mutations have been identified in Emery
Dreifuss Muscular Dystrophy (EDMD), Dilated Cardiomyopathies
(DCM), autosomal recessive arthrogryposis (ARA) and autosomal
recessive cerebellar ataxia (ARCA1) [15,17,18,50,51]. The nesprin
mutations promoting EDMD and DCM presumably affect LINC
nesprin variants resulting in abnormal nuclear morphology and
function.
ARA is caused by an A to G mutation in a splice acceptor site,
resulting in retention of intron 136 of nesprin-1 [51]. This
mutation produces a premature stop codon and therefore the
nesprin-1 giant, nesprin-1b and nesprin-1a isoforms should lack
the KASH domain. Conversely these patients appeared to have no
defects in nuclear morphology or lamin and emerin localization,
suggesting other nesprin gene products or p53KASH
Nesp1 which
should not be effected by this mutation maybe enough to keep the
nucleus intact.
ARCA1 is a neurological disease characterized by irregular gait
and lack of limb coordination [18]. Five different mutations giving
rise to ARCA1 were identified within the central spectrin rod of
nesprin-1, upstream of the KASH variants identified so far. The
A310067G mutation which effects the invariant A of the AG splice
acceptor site at the junction of exon 85 and intron 84 results in the
formation of a pre-mature stop codon and therefore will effect
production of not only the p40, p50, p31 and p23 nesprin-1
proteins identified in this study but also other variants terminating
with the N1-39E87 and N1-39E90 ends in there native tissues/
cells. Although many diseases associated with nesprins so far
suggest that NE nesprins are involved, ARCA1 patients appear to
have no nuclear defects, suggesting that nesprin associated
signalling pathways beyond the NE may be significantly hindered
and potentially causative in the disease.
Materials and Methods
Identification of Novel UTRs
Rapid Amplification of cDNA Ends (RACE) on Brain, HeLa
and Skeletal muscle Marathon-Ready cDNA libraries using the
Advantage-2 PCR kit (Clontech) and gene specific primers was
performed (Table S3). Resultant PCR fragments were cloned into
pGEM-T easy vector (Promega) and sequenced (Gene Service).
These sequences were then BLASTED against the human genome
and novel cDNA ends were further analyzed.
Additional novel UTRs for nesprin-1 and nesprin-2 were
identified by screening the NCBI expressed sequence tag (EST)
database with consecutive, 500 bp-overlapping 1 kb Nesprin-1
and Nesprin-2 sequences covering the entirety of the giant isoform
cDNAs. Tissue specificity of novel UTRs was determined by
performing PCR amplification in a multiple tissue cDNA
collection (Clontech). 30 PCR cycles were performed on 0.5 ul
of cDNA followed by a further 15 cycles on 1 ul of the amplified
Figure 5. Nesprin-1 Central rod isoforms. A) Nesprin-1 isoforms p31
Nesp1, p23
Nesp1, p12
Nesp1, p50
Nesp1, p41
Nesp1, p30
Nesp1 and p20
Nesp1 are
potential variants which could be generated through alternative initiation and termination using UTRs located between exons 83 and 90. All isoforms
except p30
Nesp1 and p20
Nesp1 PCR amplified from at least one tissue examined. B) p50
Nesp1 localized to and polymerized microtubules in U2OS cells.
p31
Nesp1 displayed a diffusive localization when transfected into U2OS cells. See Figure S1A for diffusive localization staining of p23
Nesp1, p12
Nesp1 and
p41
Nesp1. C) p23
Nesp1 and p12
Nesp1 promoted nucleolar cap formation in HDFs while p31
Nesp1 localized to the nucleolus without causing any nucleolar
disruption. D) p55
Nesp1 localized diffusively around the cytosol when transfected into U2OS cells and was detected in the kidney, spleen and
peripheral blood leukocytes (PBL) by PCR.
doi:10.1371/journal.pone.0040098.g005
Figure 6. Nesprin-1 expression is highly adaptable. Expression levels of N1-39E87, N1-39E90 and nesprin-1 KASH domain were monitored post-
siRNA knockdown using siRNAs targeting exons 90 and 136 of the nesprin-1 gene. As demonstrated si-136 increased expression of N1-39E87 whereas
si-90 reduced it’s expression. *p,0.01, ANOVA analysis, 95% confidence interval.
doi:10.1371/journal.pone.0040098.g006
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sequencing. Primers used for UTR expression can be found in
Table S4. Primers used for cassette exon splicing and detection of
nesprin DKASH variants can be found in Tables S5 and S6
respectively.
Plasmids
Isoforms p53KASH
Nesp1, p56CH
Nesp1 and p50
Nesp1 were Taq
PCR amplified from tissue cDNA and cloned into pGEM-T
Easy. The pGEM-T plasmids were subsequently used as
templates for Pfu amplification with primers containing restric-
tion sites and ligated into pCMV-Tag2 vector. p53DKASH
Nesp1
was cloned using inverse PCR with Pfu off the Flag-
p53KASH
Nesp1 vector while p50
Nesp1 served as a template for
the inverse PCR and creation of p41
Nesp1 and p30
Nesp1. The
Kazusa cDNA clone KIAA1262 served as a template for PCR
amplification and cloning of p31
Nesp1, p23
Nesp1 and p12
Nesp1
into a pCMV-Tag2 (Clontech). p32CH
Nesp2 was PCR amplified
from IMAGE clone 5478637 and cloned into pCMV-Tag2 as
described.
Tissue culture
Normal human dermal fibroblasts (HDF) and osteosarcoma
cells (U2OS) were obtained from American Tissue Culture
Table 2. Cassette exons identified through online databases.
Nesprin Exon Splicing Peptide Sequence Accession
Nesprin-1 Exon 69 Cassette SMHRGSP CF552114
Nesprin-1 Exon 93 Cassette MTAGRCHTLLSPVTEESGEEGTNSEISSPPACRSPSPVANTDASVNQ DB289567,
AK310977,
CA425673,
CA312508,
DA809350,
DB224830,
DA493464
Nesprin-1 Exon 145 Cassette VHKRWLRFLPF* BX647837
Nesprin-2 Exons 28–31 Cassette Premature stop codons AU185086
Nesprin-2 Exon 101’ Cassette PTHGVQQKYYLMMTKNAMFIREEVFQFFPMTMHFLFINVIFPKLGN
CITIIIKGQDSRDPTSLQATTALAGLYQLGRQGSTARY
CR749324
Nesprin-2 Exon 107’ Cassette DVEIPENPEAYLKMTTKTLKASS NM_182914,
DA044815,
DB138084,
DA868743
Nesprin-2 Exons 110–113 Cassette IRASSPSKVQSSENYRRRGGDREQGPRQHTATALLPLKGGPGSPTPA
AAPPAAAAPGLPAALLRRRLQLHSGQQLCPVLLPHAEVHQWATPH
IEGIAGHSATPPA*
BM725084
Nesprin-2 Exon 114 Cassette NPASPLPSFDEVDSGDQPPATSVPAPRAK BE795270
An online scan of the EST and nucleotide databases indicated that the nesprin-1 and nesprin-2 genes underwent extensive alternative splicing and this was verified
using PCR (Figure 7A,B).
*Represents a stop codon for nesprin-1 exon 145 and nesprin-2 exons 110–113.
doi:10.1371/journal.pone.0040098.t002
Figure 7. Identification of nesprin-1 and nesprin-2 splicing events. A) PCR amplification across splice sites was carried out from cDNA
isolated from U2OS cells. Splicing of exon 93 for nesprin-1 was observed as was the splicing for nesprin-2 exon 107’. B) PCR amplification across splice
sites was carried out from cDNA isolated from VSMCs. Splicing of exon 93 for nesprin-1 was observed. Exon 107’ was retained in all nesprin-2
transcripts while splicing of exons 110–113 was also observed in these cells.
+Represents bands with exon(s) excluded.
doi:10.1371/journal.pone.0040098.g007
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confluency and maintained in DMEM complete media (Sigma)
supplemented with 10 units/mL penicillin, 10 mg/mL strepto-
mycin, 200 mM L-glutamine and 10% FBS.
Transfections
For Flag-tagged construct expression, 1610
6 HDFs or U2OS
cells were electroporated with 1 mg plasmid DNA using an Amaxa
Nucleofector and cultured on coverslips for 16 hours.
Immunofluorescence
Cells were fixed for 5 minutes in 3.7% paraformaldehyde in
PBS followed by 2 min permeabilization with 0.5% NP-40 in
PBS. The coverslips were incubated with blocking solution (1%
BSA) for 1 hour at RT. The primary antibodies were diluted in
blocking solution and applied to the coverslips for 1 hour at
RT, followed by a 1 hour RT incubation with fluorescent dye-
conjugated secondary antibodies (Invitrogen) diluted in blocking
solution. The coverslips were washed with PBS, mounted onto
Figure 8. Generation of nesprin-1 and nesprin-2 DKASH variants. A) Nesprin-1DKASH is generated through the removal of cassette exon 145,
resulting in disruption of the KASH domain. Ectopically expressed p53DKASH
Nesp1 fails to localize to the NE in U2OS cells and is strongly concentrated
within the nucleus and weakly in the cytosol. B) Nesprin-2DKASH1 is generated though the removal of exons 111–112 through the splicing event
described in the previous section (splicing shown in red). C) Nesprin-2DKASH2 is generated through utilization of an alternative 39UTR juxtaposed to
exon 115. D) PCR-based tissue screen for DKASH variants shows that the removal of exon 145 for Nesprin-1DKASH is detected in a wide array of
tissues. Nesprin-2DKASH1 splicing is detected pre-dominantly in the brain and kidney with small amounts also detected in the heart.
+denotes the
spliced Nesprin-2DKASH1 product. Nesprin-2DKASH2 was detected in the heart and spleen only. Peripheral Blood Leukocytes (PBL).
doi:10.1371/journal.pone.0040098.g008
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Leica SP5 confocal microscope or a Zeiss Axioskop microscope.
siRNA Knockdown and qRT-PCR
U2OS cells were transfected with siRNAs for nesprin-1 or
control siRNA using hiperfect transfection reagent (Quiagen) as
described by the manufacturer. Three days post-transfection total
RNA was obtained from cells using Triazole RNA STAT-60 and
phenol chloroform extraction. 2 mg of total RNA was reverse
transcribed using AMV Reverse Transcriptase (Promega) accord-
ing to the manufacturer’s instructions. qPCR was performed in a
20 ml reaction containing cDNA per 16 SYBR Green PCR
master mix (Eurogentec) and 0.1 mM of each primer. PCR
products were amplified, N1-39E87 primers (forward, 59-
TCTCCAAGCTCAATCAGGCAGCAT -39 and reverse, 59-
CACAGCCCTCTAAGTGTTGTGTCA -39), N1-39E90 primers
(forward, 59- AGTTGGACGTCTCAGTCTCAAGGA -39 and
reverse, 59- TTTGATGGCTGAGCCCACACAATG -39),
KASH primers (forward, 59-CGAGGCAAGTGTAGTCTCT-
CACAG-39 and reverse, 59-AGGGCCATTCGTGTATCTGAG-
CAT-39) and GAPDH primers (forward, 59-CGACCACTTTGT-
CAAGCTC-39 and reverse, 59-
CAAGGGTCTACATGGCAAC-39). The cycling parameters
were 94uC for 15 seconds followed by a single step annealing
and extension at 60uC for 60 seconds. Amplifications were
performed on RotorGene-3000 (Corbett). Fold changes between
samples were calculated by the delta-delta CT method.
Supporting Information
Figure S1 Localizations of p23
Nesp1, p12
Nesp1 and
p41
Nesp1. A) p23
Nesp1, p12
Nesp1 and p41
Nesp1 displayed diffusive
cytoplasmic localization when transfected into U2OS cells. B)
p41
Nesp1 displayed diffusive localization and concentrated around
the ER when transfected into HDFs.
(TIF)
Figure S2 Schematics of nesprin-1 and nesprin-2 cas-
sette exons. A) Nesprin-1 genomic map showing the location of
nesprin-1 cassette exon 69 (Red box). B) Nesprin-2 genomic map
showing the location of nesprin-2 cassette exons 101’ (orange box)
and107’ (Purple box).
(TIF)
Table S1 UTR combinations used to generate potential
nesprin-1 variants. Nesprin-1 can generate multiple variants
through the use of alternative UTRs in a ‘mix-and-match’
approach. The tables highlight the UTR pairs used to generate
the potential isoforms described in Figures 2B.
(DOCX)
Table S2 UTR combinations used to generate potential
nesprin-2 variants. Nesprin-2 can generate multiple variants
through the use of alternative UTRs in a ‘mix-and-match’
approach. The tables highlight the UTR pairs used to generate
the potential isoforms described in Figures 3B.
(DOCX)
Table S3 Primers used for 59 and 39 RACE. Primers and
nested primers used for detection of novel nesprin-1 and nesprin-2
cDNA ends.
(DOCX)
Table S4 Primers used for UTR detection. Forward and
reverse primers used for detection of novel nesprin-1 and nesprin-2
UTRs. Forward and reverse primers were separated by at least 1
coding exon to control for genomic contamination.
(DOCX)
Table S5 Primers used for detection of cassette exons.
Forward and reverse primers used for detection of novel nesprin-1
and nesprin-2 cassette exons.
(DOCX)
Table S6 Primers used for the detection of DKASH
variants. Forward and reverse primers used for detection of
nesprin-1 and nesprin-2 DKASH variants.
(DOCX)
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